SEC Filing | GlycoMimetics, Inc.

View:

SEC FORM 3 SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Johnson Bruce S

(Last)

(First)

(Middle)

C/O GLYCOMIMETICS, INC.

9708 MEDICAL CENTER DRIVE

(Street)

ROCKVILLE

20850

(City)

(State)

(Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
03/23/2023

3. Issuer Name and Ticker or Trading Symbol
GLYCOMIMETICS INC [ GLYC ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
SVP & Chief Commercial Officer

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	125,480	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
Employee Stock Option (right to buy)	⁽¹⁾	02/15/2032	Common Stock	235,000	1.07	D
Employee Stock Option (right to buy)	⁽²⁾	01/18/2033	Common Stock	200,000	2.55	D

Explanation of Responses:

1. The award was comprised of (i) an option to purchase 200,000 shares of the Issuer's common stock, which vested as to 25% of the underlying shares on February 16, 2023 and which will vest as to the remaining shares in equal monthly installments over 36 months thereafter, and (ii) an option to purchase 35,000 shares of common stock, which will vest as to one-half of the underlying shares upon FDA approval of the Issuer's product candidate uproleselan as a treatment for relapsed/refractory acute myeloid leukemia and the remaining one-half of the underlying shares upon the first commercial sale of uproleselan in the United States or abroad, subject in each case to the Reporting Person's continued service with the Issuer through the applicable vesting date.

2. 25% of the shares underlying this option will vest on January 19, 2024 and the remaining shares will vest in equal monthly installments over 36 months thereafter, subject to the Reporting Person's continued service with the Issuer through each such vesting date.

Remarks:

	/s/ Brian F. Leaf, as attorney-in-fact	03/31/2023
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

POWER OF ATTORNEY
(For Executing Form ID and Forms 3, 4 and 5)

Know all by these presents that the undersigned hereby constitutes and appoints
each of Brian Leaf, Katie Kazem, Caroline Diemer, Alexandre Rotival, Cortney
Smith of Cooley LLP, and Brian M. Hahn, Christian Dinneen-Long and Stephanie R.
Irish of GlycoMimetics, Inc. (the Company) signing individually, the
undersigneds true and lawful attorney-in-fact and agents to:

(1)	Prepare, execute in the undersigneds name and on the undersigneds behalf,
and submit to the Securities and Exchange Commission (the SEC) a Form ID,
including amendments thereto, and any other documents necessary or appropriate
to obtain codes and passwords enabling the undersigned to make electronic
filings with the SEC of reports required by Section 16(a) of the Securities
Exchange Act of 1934, as amended (the Exchange Act), or any rule or regulation
thereunder;

(2)	Prepare, execute in the undersigneds name and on the undersigneds behalf,
and submit to the SEC Forms 3, 4 and 5 (including amendments thereto and joint
filing agreements in connection therewith) in accordance with Section 16(a) of
the Exchange Act and the rules thereunder;

(3)	Do and perform any and all acts for and on behalf of the undersigned that
may be necessary or desirable to prepare, complete and execute any such Form 3,
4 or 5 (including amendments thereto and joint filing agreements in connection
therewith) and timely file such forms with the SEC and any stock exchange,
self-regulatory association or any other authority; and

(4)	Take any other action of any type whatsoever in connection with the
foregoing that, in the opinion of any such attorney-in-fact, may be necessary or
desirable in connection with the foregoing authority, it being understood that
the documents executed by any such attorney-in-fact on behalf of the undersigned
pursuant to this Power of Attorney shall be in such form and shall contain such
terms and conditions as the attorney-in-fact may approve in the
attorney-in-facts discretion.
The undersigned hereby grants to each such attorney-in-fact full power and
authority to do and perform any and every act and thing whatsoever requisite,
necessary, or proper to be done in the exercise of any of the rights and powers
herein granted, as fully to all intents and purposes as the undersigned might or
could do if personally present, with full power of substitution or revocation,
hereby ratifying and confirming all that such attorney-in-fact, or such
attorney-in- facts substitute or substitutes, shall lawfully do or cause to be
done by virtue of this Power of Attorney and the rights and powers herein
granted.  The undersigned acknowledges that the foregoing attorneys-in-fact, and
their substitutes, in serving in such capacity at the request of the
undersigned, are not assuming any of the undersigneds responsibilities to comply
with Section 16 of the Exchange Act.
This Power of Attorney shall remain in full force and effect until the
undersigned is no longer required to file Forms 3, 4 and 5, unless earlier
revoked by the undersigned in a signed writing delivered to the
attorneys-in-fact or, as to any attorney-in-fact individually, such
attorney-in-fact is no longer affiliated with Cooley LLP, as applicable.  This
Power of Attorney revokes any other power of attorney that the undersigned has
previously granted to representatives of Cooley LLP.  This Power of Attorney may
be filed with the SEC as a confirming statement of the authority granted herein.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be
executed as of the date written below.

Dated: March 13, 2023




By:	/s/ Bruce Johnson
	Name: Bruce Johnson